YXT.com Receives Nasdaq Noncompliance Notice, Granted 180 Days, Or Until July 27, 2026 To Regain Compliance

YXT.com Group Holding Limited (NASDAQ:YXT) ("YXT.com" or the "Company"), a provider of AI-enabled enterprise productivity solutions, today announced that it has received a written notification (the "Deficiency Letter") from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") dated January 26, 2026, indicating that for the last 30 consecutive business days, the closing bid price of the Company's American depositary shares (the "ADSs") was below the minimum bid price of US$1.00 per share requirement set forth in Nasdaq Listing Rule 5450(a)(1). The Deficiency Letter has no current effect on the listing or trading of the Company's ADSs on Nasdaq.

Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until July 27, 2026 (the "Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price of the Company's ADSs is at least US$1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed.

In the event that the Company does not regain compliance by July 27, 2026, subject to the determination by the staff of Nasdaq, the Company may be eligible for additional time. To qualify, the Company must submit, no later than July 27, 2026, a transfer application to listing on the NASDAQ Capital Market. The Company will be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards, with the exception of the bid price requirement, and will need to provide written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split if necessary. As part of its review process, Nasdaq will make a determination of whether it believes the Company will be able to cure this deficiency. Should Nasdaq conclude that the Company will not be able to cure the deficiency, or should the Company determine not to submit a transfer application or make the required representation, Nasdaq will provide notice that its securities will be subject to delisting.

The Company intends to monitor the closing bid price of its ADSs between now and July 27, 2026 and is considering its options in order to regain compliance with the Nasdaq minimum bid price requirement. The Deficiency Letter does not affect the Company's business operations, its U.S. Securities and Exchange Commission reporting requirements or contractual obligations.